PFA-100 analysis upon addition of either dasatinib or imatinib to fresh whole blood obtained from healthy controls
| Treatment/time . | Epinephrine (normal <160 seconds) . | ADP (normal <120 seconds) . |
|---|---|---|
| No drug*, baseline | 112† | 80† |
| DMSO 0.2%, baseline | 100 | 72 |
| Dasatinib, min | ||
| 0 | 126 | 77 |
| 30 | > 300 | 84 |
| 60 | 297 | 87 |
| 120 | > 300 | 86 |
| Imatinib, min | ||
| 0 | 86 | 93 |
| 30 | 89 | 126 |
| 60 | 94 | 114 |
| 120 | 70 | 131 |
| Treatment/time . | Epinephrine (normal <160 seconds) . | ADP (normal <120 seconds) . |
|---|---|---|
| No drug*, baseline | 112† | 80† |
| DMSO 0.2%, baseline | 100 | 72 |
| Dasatinib, min | ||
| 0 | 126 | 77 |
| 30 | > 300 | 84 |
| 60 | 297 | 87 |
| 120 | > 300 | 86 |
| Imatinib, min | ||
| 0 | 86 | 93 |
| 30 | 89 | 126 |
| 60 | 94 | 114 |
| 120 | 70 | 131 |
Dasatinib (400 nM) rapidly induced prolongation of closure times from 100 seconds at baseline to > 300 seconds in response to epinephrine (but not in response to ADP) after only 30 minutes of incubation. In contrast, imatinib (400 nM) did not prolong closure times.
“No drug” indicates citrated blood only without the addition of DMSO (drug solvent), dasatinib, or imatinib.
Mean value of 2 experiments.